Suzhou Abogen Biosciences Co., Ltd.

This early-stage trial tests a new mRNA vaccine (ABO1105) against respiratory syncytial virus (RSV) in 96 healthy adults aged 18 and older. The main goal is to check the vaccine's safety and how well the body's immune system responds. Participants receive one injection at one of …

This early-stage trial tests a new mRNA vaccine (ABO1108) for shingles in 180 healthy adults aged 40 and older. Participants receive two shots about two months apart at different dose levels. The study focuses on safety and how well the vaccine triggers an immune response.

This study tests a new mRNA vaccine (ABO1105) against respiratory syncytial virus (RSV) in 420 healthy adults aged 50 and older. Participants receive one injection of either a low or high dose of the vaccine or a placebo. The goal is to see how well the vaccine boosts the immune …

This study tests a new mRNA vaccine (ABO1108) to see if it can safely prevent shingles in adults aged 40 and above. Around 300 healthy participants will receive two shots, two months apart, and be compared to a placebo group. The goal is to measure the body's immune response and …